甲状腺激素受体-β类似物治疗代谢功能障碍相关脂肪性肝炎(MASH)
综述阐述甲状腺功能欠佳与代谢综合征及MASLD的关联,MASH中肝内甲状腺激素浓度低且THR激活减弱。选择性THR-β激动剂可靶向肝脏减少肝甘油三酯和LDL胆固醇,减少心血管副作用。最先进化合物resmetirom在大型III期试验中减少肝脏脂肪、降低转氨酶、改善致动脉粥样硬化性血脂异常且耐受性良好,组织学改善获加速批准用于活动性纤维化脂肪性肝炎,为首个MASH药物。
要点
- 甲状腺功能欠佳与代谢综合征及MASLD的关联已明确,MASH中肝内甲状腺激素浓度低且THR激活减弱。
- 选择性THR-β激动剂对THR-α亲和力降低且组织分布不同,减少不必要的心血管副作用。
- resmetirom在MASH大型III期试验中减少肝脏脂肪、降低转氨酶、改善致动脉粥样硬化性血脂异常且耐受性良好。
核心结论
- resmetirom在MASH大型III期试验中减少肝脏脂肪、降低转氨酶水平并改善致动脉粥样硬化性血脂异常,耐受性良好,组织学改善促成其获加速批准用于活动性纤维化脂肪性肝炎,为首个MASH药物。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 甲状腺功能欠佳(亚临床或临床甲状腺功能减退或正常低值甲状腺功能)与代谢综合征及MASLD的关联已明确。
- MASH中肝内甲状腺激素浓度低且甲状腺激素受体(THR)激活减弱。
- 给予甲状腺激素可通过脂噬和β氧化刺激脂肪酸处置减少肝脏甘油三酯并降低LDL胆固醇。
- 选择性THR-β激动剂对THR-α核受体亲和力降低且组织分布与内源性甲状腺激素不同,减少不必要的心血管副作用。
- resmetirom为口服药物,在MASH大型III期试验中减少肝脏脂肪、降低转氨酶水平并改善致动脉粥样硬化性血脂异常,耐受性良好。
关键数值与推荐
- resmetirom在MASH大型III期试验中显示减少肝脏脂肪、降低转氨酶水平、改善致动脉粥样硬化性血脂异常且耐受性良好,并获加速批准用于活动性纤维化脂肪性肝炎。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The association between suboptimal thyroid function ((sub)clinical hypothyroidism or low-normal thyroid function) and the metabolic syndrome and MASLD (metabolic dysfunction-associated steatotic liver disease) has been clearly established. Furthermore, in MASLD, intracellular thyroid hormone concentrations are low and the activation of the thyroid hormone receptor (THR) is reduced. Administration of thyroid hormone has been shown to reduce liver triglycerides by stimulating fatty acid disposal through lipophagy and beta-oxidation, and to lower LDL-cholesterol. As thyroid hormone exerts its effects in many different organs, including the heart and bone, several drug candidates have been developed as selective thyromimetics for the THR-β nuclear receptor with potent and liver-targeted activity. Importantly, these compounds have reduced affinity for the THR-α nuclear receptor and tissue distribution profiles that differ from endogenous thyroid hormones, thereby reducing unwanted cardiovascular side effects. The most advanced compound, resmetirom, is an oral drug that demonstrated, in a large phase III trial in patients with MASH (metabolic dysfunction-associated steatohepatitis), the ability to reduce liver fat, decrease aminotransferase levels and improve atherogenic dyslipidaemia with a good tolerability profile. This translated into histological improvement that led to accelerated approval of this drug for active fibrotic steatohepatitis, a milestone achievement as a first MASH drug.
引用
- Ratziu V, Scanlan TS, Bruinstroop E, et al. Thyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). J Hepatol. 2024. PMID: 39428045. doi:10.1016/j.jhep.2024.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。